A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer

Diana V. Maslov; Quinne Sember; Jason Cham; Munveer Bhangoo

doi:10.3389/fonc.2023.1150777

Frontiers in Oncology (Mar 2023)

A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer

Diana V. Maslov,
Quinne Sember,
Jason Cham,
Munveer Bhangoo

Affiliations

Diana V. Maslov: Department of Hematology/Oncology, Scripps Health System, San Diego, CA, United States
Quinne Sember: Department of Hematology/Oncology, Scripps Health System, San Diego, CA, United States
Jason Cham: Scripps Clinic/Green Hospital, Department of Internal Medicine, San Diego, CA, United States
Munveer Bhangoo: Department of Hematology/Oncology, Scripps Health System, San Diego, CA, United States

DOI: https://doi.org/10.3389/fonc.2023.1150777
Journal volume & issue: Vol. 13

Abstract

Read online

Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant. Many treatments have been shown to improve progression free survival and overall survival in metastatic castration resistant prostate cancer (mCRPC). In recent years, studies have been exploring targeting mutations in the DNA Damage Repair (DDR) response that may amplify oncogenes. In this paper, we aim to discuss DDR, new approved targeted therapies, and the most recent clinical trials in the setting of metastatic CRPC.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords